Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy is organized by Clinical Care Options (CCO), LLC.,Released: April 10, 2023,Expiration: April 09, 2024,Program Learning Goal:,The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer,• Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer,• Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials,• Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy,• Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer,• Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials